Francis Crick Institute scientists, funded by Cancer Research UK, have solved a decades-old mystery and helped to unravel the genetic cause of some breast and ovarian cancers, according to new research published in the journal Cell.
Following a five-year study in nematode worms, researchers have uncovered how key proteins can switch on a protein called RAD51, allowing it to repair cancer-causing DNA damage in cells.
Women with faulty RAD51 and BRCA1 and BRCA2 genes are at higher risk of developing breast and ovarian cancer. Scientists already knew how proteins produced by these genes work hand-in-hand to fix DNA damage, and why faults can lead to disease.
Defects in protein cousins of RAD51 also increase the risk of these cancers. But scientists didn't know how.
The team has now revealed how these protein cousins work to switch on RAD51 by changing its shape - which dramatically boosts its DNA-repair powers.
Dr Simon Boulton, lead author and group leader at the Francis Crick Institute, said: "These protein cousins - known as paralogs - have been an enigma for about 30 years. But now we know they are right at the heart of repairing cell damage and helping to stop breast and ovarian cancers developing. In fact they have as vital a role as the more well-known BRCA genes in preventing the disease.
"Knowing how these proteins work won't make an immediate difference to cancer patients, but it's another piece of the cancer jigsaw puzzle which could lead to more effective and kinder treatments in the future."
Breast cancer is the UK's most common cancer, with around 50,000 women diagnosed each year. Ovarian cancer is the fifth most common cancer in UK women, with more than 7,000 cases diagnosed annually. More than one in 20 ovarian cancers and breast cancers are due to an inherited genetic fault. Experimental drugs called PARP inhibitors target cancers in people with inherited mistakes in the BRCA1 or BRCA2 genes. In the future, cancer patients who have inherited faulty protein cousins could potentially benefit from these types of drugs.
Nell Barrie, senior science communications manager at Cancer Research UK, said: "Understanding the nuts and bolts of cancer is vital if we are to beat this disease. This landmark discovery reveals another potential chink in cancer's armour - and it could help lead to more personalised treatments that take patients' genetic make-up into account and ultimately save more lives."
For media enquiries contact the Cancer Research UK press office on 020 3469 8300 or, out of hours, on 07050 264 059.
Notes to editor:
Notes to editor:'Rad51 paralogs remodel pre-synaptic Rad51 filaments to stimulate homologous recombination' Taylor, M.R.G., Špírek, M., Chaurasiya, K.R., Ward, J.D., Carzaniga, R., Yu, X., Egelman, E.H., Collinson, L.M., Rueda, D., Krejčí, L. and Boulton, S.J. (2015). DOI: 10.1016/j.cell.2015.06.015
The research was funded by Cancer Research UK, the European Research Council and other international funding agencies. Researchers were based at the London Research Institute, now part of the Francis Crick Institute; Masaryk University in Brno, Czech Republic; Imperial College London; and the University of Virginia.
About the Francis Crick Institute
About the Francis Crick Institute
The Francis Crick Institute will be a world-leading centre of biomedical research and innovation. It will promote connections between researchers, between disciplines, and between academic institutions, healthcare organisations and businesses. Dedicated to research excellence, the institute will have the scale, vision and expertise to tackle challenging scientific questions underpinning health and disease.
Due to open in 2015, the Francis Crick Institute is a charity supported by the Medical Research Council, Cancer Research UK, the Wellcome Trust, UCL (University College London), Imperial College London and King's College London. It will be world-class with a strong national role - training scientists and developing ideas for public good. http://www. About Cancer Research UK
About Cancer Research UK
- Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
- Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
- Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years.
- Today, 2 in 4 people survive cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive cancer within the next 20 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.